Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.
According to Office for National Statistics, on healthcare in 2018. This was equivalent to approximately 10.0% of GDP, which was high in comparison to 9.8% in 2017. The market growth in the country can primarily be attributed to the presence of a large geriatric population and rising awareness about rare diseases.
In England, 21,219 finished consultant episodes, 16,408 admissions, and 97,598 bed days were reported for malignant neoplasm of the brain. The treatment of GBM varies in countries, and in the UK, the standard of care is surgery followed by radiation and chemotherapy (Temozolomide) in newly diagnosed cases.
However, for recurrent/relapsed cases, the treatment approaches are palliative. Moreover, 30% of patients not eligible for surgery receive steroids. This creates huge opportunity for novel emerging therapies in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the UK glioblastoma multiforme treatment market , including forecasts for subscribers. This country databook contains high-level insights into UK glioblastoma multiforme treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account